Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


2nd World Congress on Health Economics Policy & Outcomes Research

Madrid, Spain

Barbara Mascialino

Barbara Mascialino

Thermo Fisher Scientific ImmunoDiagnostics | Swedan

Title: The pre-endoscopic screening test EliA Calprotectin 2 is a cost-saving technique compared to serological markers and colonoscopy: The Japanese perspective


Biography: Barbara Mascialino


The majority of bowel disorders exhibit overlapping symptoms, making diagnosis difficult in primary care (PC). Inflammatory bowel diseases (IBDs) are characterized by chronic inflammation of the gastrointestinal tract; irritable bowel syndrome (IBS) is a functional disorder, with prevalence 10-20%. Endoscopy is the gold standard for detecting and quantifying IBDs, but due to its low prevalence (in Japan: 152x105 persons), it turns negative in most cases, it is expensive, uncomfortable and risky for the patient. F-Calprotectin is a fecal marker of intestine inflammation that can be used as a pre-endoscopic technique to rule out IBDs.

EliA Calprotectin 2 is expected to be launched into the Japanese market in 2017. The present study aims at evaluating the cost-effectiveness of a) EliA Calprotectin 2 test compared to the b) usage of serologic markers CRP and ESR, c) combined usage of these tests, and d) gold standard to distinguish IBD from IBS in Japan.

Methodology: A 18-weeks Markov model was developed for each diagnostic strategy, simulating 1000 patients presenting to PC with unspecific gastrointestinal symptoms. Outcomes include cost savings, cost per corrected IBD diagnosed, and colonoscopies reduction (including their complications). Uncertainty was addressed with sensitivity analysis.

Findings: Table 1 shows that EliA Calprotectin 2 is cost-effective compared to CRP+ESR, and to colonoscopy; it:

1) Results in more corrected IBD diagnoses at a lower price;

2) Reduces the number of unnecessary endoscopies, increasing the number of correctly diagnosed IBD (N=63) and IBS (N=26) patients.

Conclusion: Results show that the usage of EliA Calprotectin 2 as pre-endoscopic diagnostic tool is associated with less colonoscopies, and important cost savings ascribable to reduced resource utilization. F-Calprotectin is a dominant strategy in relation to the comparators; it should be recommended for reimbursement in Japan, and can be considered as good value for money for the health insurance system.


EliA Calprotectin 2



Total costs (YEN)

17 913 568

22 232 221

33 102 599

Average cost/patient (YEN)

17 914

22 232

33 103

N colonoscopies avoided




Colonoscopy- costs avoided (YEN)

22 271 517

21 863 202


N correctly diagnosed IBS




N correctly diagnosed IBD




Colonoscopy -complications costs (YEN)

45 955

50 835

141 504

Table 1 shows that EliA Calprotectin 2 is cost-effective compared to CRP+ESR, and to colonoscopy;

Recent Publications

  1. Lin W-C et al. (2015). Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol; Dec; 21(48):13566-73. doi: 10.3748/wjg.v21.i48.13566.
  2. Bellini M et al. (2011). Evaluation of latent links between irritable bowel syndrome and sleep quality. World J Gastroenterol Dec 14;17(46):5089-96. doi: 10.3748/wjg.v17.i46.5089.
  3. Ng W-K et al. (2016). Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 14(2): 111-119. doi: 10.5217/ir.2016.14.2.111. Epub 2016 Apr 27.
  4. Tibble JA et al. (2002). Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology Aug;123(2):450-60.
  5. Yang Z et al. (2014). Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol.; Feb;12(2):253-62.e2. doi: 10.1016/j.cgh.2013.06.028. Epub 2013 Jul 21.
  6. Ranasinghe I et al (2015). Differences in colonoscopy quality among facilities: development of a post-colonoscopy risk-standardized rate of unplanned hospital visits. Gatroenterology. Jan;150(1):103-13. doi: 10.1053/j.gastro.2015.09.009. Epub 2015 Sep 25.


Speaker Presentations

Speaker PPTs Click Here